| 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司核算 | 2024 年期初占 | 2024 年度占用累计 | 2024 年度占用资 | 2024 | 年度偿还 | 2024 年期末占 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 的会计科目 | 用资金余额 | 发生金额（不含利息） | 金的利息（如有） | | 累计发生金额 | 用资金余额 | 原因 | | | 控股股东、实际控制 | —— | —— | —— | - | - | | - | - | | - —— | —— | | 人及其附属企业 | | | | | | | | | | | | | 小计 | —— | —— | —— | - | - | | - | - | | - —— | —— | | 前控股股东、实际控 | —— | —— | —— | - | - | | - | - | | - —— | —— | | 制人及其附属企业 | | | | | | | | ...

证券代码：300247 证券简称：融捷健康 公告编号：2024－022 融捷健康科技股份有限公司 第六届监事会第八次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏。 一、监事会会议召开情况 融捷健康科技股份有限公司（以下简称"公司"）第六届监事会第八次会议通知于 2024 年 08 月 17 日以电子邮件方式发出，本次会议于 2024 年 08 月 27 日上午在融捷 健康合肥总部九楼会议室以现场结合通讯方式召开。会议由监事会主席贾小慧女士主 持，本次应出席会议的监事 3 人，实际出席会议的监事 3 名。本次会议符合《公司法》 及《公司章程》的有关规定。 二、监事会会议审议情况 1、审议通过《关于公司<2024年半年度报告>及其摘要的议案》 监事会认为：公司编制《2024 年半年度报告》及其摘要的程序符合法律、行政法 规和中国证监会的规定，报告内容公允地反映了公司的经营状况和经营成果，报告所 披露的信息真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 《2024年半年度报告》及《2024年半年度报告摘要》具体内容详见刊登于中国证 监会指定创业板 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥333,381,515.02, representing a 22.93% increase compared to ¥271,201,740.22 in the same period last year[10]. - The net profit attributable to shareholders of the listed company was ¥28,676,352.56, a 36.30% increase from ¥21,039,872.14 in the previous year[10]. - The net profit after deducting non-recurring gains and losses was ¥28,119,976.96, up 36.58% from ¥20,588,582.07 year-on-year[10]. - The basic earnings per share increased to ¥0.0357, reflecting a growth of 36.26% compared to ¥0.0262 in the previous year[10]. - The company reported a net profit of CNY 3,292.64 million from its overseas subsidiary, Golden Designs INC., representing 24.14% of the company's net assets[28]. - The company reported a total comprehensive income of ¥40,422,796.60 for the first half of 2024, compared to ¥38,365,063.88 in the same period of 2023[82]. - The total profit for the first half of 2024 is CNY 1,880,573.51, compared to CNY 5,314,515.77 in the same period of 2023, indicating a significant decrease[85]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,258,411,430.42, a 3.02% increase from ¥1,221,559,067.16 at the end of the previous year[10]. - The net assets attributable to shareholders of the listed company were ¥1,045,678,103.02, which is a 2.84% increase from ¥1,016,847,716.12 at the end of the previous year[10]. - The total liabilities increased to ¥206,091,684.12, compared to ¥203,461,306.01 in the previous year[81]. - The total equity attributable to owners of the parent company was reported at -¥1,150,076,756.94, slightly improved from -¥1,151,957,330.45 year-over-year[81]. - The total owner's equity at the end of the period is 1,028,773,301.73 CNY, which includes minority interests of 39,817,903.29 CNY[93]. Cash Flow - The net cash flow from operating activities was ¥39,912,213.21, down 51.52% from ¥82,330,869.57 in the previous year[10]. - Cash inflow from operating activities totaled CNY 339,773,848.09, an increase from CNY 293,125,832.97 year-over-year[86]. - The company reported a net cash flow from investment activities of CNY 55,825,175.38, a recovery from a negative cash flow of CNY -20,151,712.95 in the previous year[87]. - The total cash outflow from investment activities was CNY 310,662,663.82, compared to CNY 37,747,122.06 in the previous year[87]. - The company's cash and cash equivalents increased to ¥209,490,134.39 from ¥119,150,981.53 at the beginning of the period, representing a growth of approximately 75.7%[74]. Research and Development - Research and development expenses increased by 35.46% to ¥5,306,502.30, reflecting the company's commitment to product innovation and competitiveness[22]. - The company aims to increase R&D investment and expand its R&D team to address challenges in new product development and innovation pressures[43]. Market Strategy - The company plans to diversify its market strategy to mitigate international market risks, particularly in the U.S. market, where it has significant sales exposure[43]. - The company will enhance market research and analysis to adapt its products and services to meet the increasing demand for functional health products, focusing on smarter and more personalized offerings[43]. Financial Health - The company has no interest-bearing debt, indicating strong financial health and risk resilience[18]. - The company has not made any changes to the fundraising projects during the reporting period[36]. - The company has not engaged in derivative investments or entrusted loans during the reporting period[38][39]. Shareholder Information - The total number of shares outstanding is 804,040,313, with 99.90% being unrestricted shares[63]. - The largest shareholder, Rongjie Investment Holding Group Co., Ltd., holds 14.54% of shares, totaling 116,912,302 shares[67]. - The annual shareholders' meeting had a participation rate of 21.84% and approved several key reports and proposals, including the financial settlement report for 2023[45]. Inventory and Receivables - The inventory balance at the end of the period was ¥160,168,396, compared to ¥143,590,254 at the beginning, indicating an increase of about 11.5%[196]. - The accounts receivable at the end of the period totaled ¥49,386,595.44, up from ¥45,112,154.71 at the beginning, indicating an increase of approximately 9.9%[181]. - The bad debt provision for accounts receivable was ¥3,758,302.56, with a provision rate of 7.61%[182]. Compliance and Governance - The half-year financial report has not been audited, and there are no significant litigation or arbitration matters reported[49]. - The company has confirmed that there are no violations of trust by its controlling shareholders or actual controllers[52]. - The company has not reported any changes in accounting policies or corrections of prior period errors during the current period[90]. Environmental and Social Responsibility - There were no significant environmental penalties or issues reported during the period, and the company has taken measures to reduce carbon emissions[47].

经中国证券监督管理委员会《关于核准融捷健康科技股份有限公司向潘建忠 等发行股份购买资产并募集配套资金的批复》（证监许可[2016]2053 号）核准， 公司于 2016 年 11 月 8 日向潘建忠、黄小霞合计发行股份 19,444,444 股、支付现 金 8,200 万元购买相关资产；向陈伟、李江合计发行股份 15,555,556 股、支付现 金 6,360 万元购买相关资产；并于 2016 年 11 月 8 日向特定投资者鹏华资产管理 （深圳）有限公司、安徽皖投工业投资有限公司、安徽高新毅达皖江产业发展创 业投资基金（有限合伙）、新华基金管理股份有限公司、财通基金管理有限公司 发行人民币普通股 47,507,953 股（以上每股发行价均为人民币 9.43 元）募集配 套资金，应募集资金金额为人民币 447,999,996.79 元，扣除发行费用人民币 21,143,875.11 元，实际募集资金净额为人民币 426,856,121.68 元。 截至 2016 年 11 月 9 日止，上述资金已全部到达本公司并入账，并经华普天 健会计师事务所（特殊普通合伙）验证，出具了"会验字[2016]4960 号"《验 ...

证券代码：300247 证券简称：融捷健康 公告编号：2024-023 融捷健康科技股份有限公司 关于以定期存单和结构性存款进行质押向银行 申请开具银行承兑汇票或信用证的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 融捷健康科技股份有限公司（以下简称"公司"）于 2024 年 08 月 27 日召开 第六届董事会第十一次会议和第六届监事会第八次会议，审议通过了《关于以定 期存单和结构性存款进行质押向银行申请开具银行承兑汇票或信用证的议案》， 现将具体情况公告如下： 一、基本情况 为提高资金使用效率，满足生产经营需要，公司拟用定期存单和结构性存款 进行质押向银行申请开具银行承兑汇票或信用证，质押总额不超过人民币 5000 万 元，用于日常经营周转及货款或费用支付，从而增加银承或信用证结算，提高资 金使用效率。该额度自公司董事会审议通过之日起一年内有效；在有效期限内， 该额度可滚动使用。 为便于管理，上述议案审议通过后，公司第六届董事会第二次会议和第六届 监事会第二次会议审议批准的质押额度、质押期限将不再继续使用。 董事会授权公司管理层具体决策上述相关事宜，具 ...

融捷健康科技股份有限公司 第六届董事会第十一次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏。 证券代码：300247 证券简称：融捷健康 公告编号：2024－021 一、董事会会议召开情况 融捷健康科技股份有限公司（以下简称"公司"、"融捷健康"）第六届董事 会第十一次会议通知于 2024 年 08 月 17 日以电子邮件的形式向各位董事发出。 本次会议于 2024 年 08 月 27 日下午以现场结合通讯的方式召开，会议由董事长 邢芬玲女士主持，本次会议应出席会议董事 6 人，实际出席会议董事 6 人。本 次会议的召集、召开及表决程序符合《公司法》等相关法律法规以及《公司章 程》的有关规定；本次会议决议合法、有效。 二、董事会会议审议情况 1、审议通过《关于公司<2024年半年度报告>及其摘要的议案》 董事会认为：公司编制《2024 年半年度报告》及其摘要的程序符合法律、 行政法规和中国证监会的规定，报告内容公允地反映了公司的经营状况和经营 成果，报告所披露的信息真实、准确、完整，不存在虚假记载、误导性陈述或 重大遗漏。 本议案已经公司董事会审计委 ...

一、召开会议的基本情况 1、股东大会届次：2023 年年度股东大会。 证券代码：300247 证券简称：融捷健康 公告编号：2024-017 融捷健康科技股份有限公司 关于召开 2023 年年度股东大会的提示性公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 融捷健康科技股份有限公司（以下简称"公司"）于 2024 年 04 月 22 日召 开第六届董事会第九次会议，定于 2024 年 05 月 14 日召开 2023 年年度股东大会。 现将本次股东大会的相关事项通知如下： 2、股东大会召集人：融捷健康科技股份有限公司董事会。 3、会议召开的合法、合规性：经本公司第六届董事会第九次会议审议通过， 决定于 2024 年 5 月 14 日召开公司 2023 年年度股东大会，会议召集程序符合有 关法律、行政法规、部门规章、规范性文件和公司章程的规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2024 年 5 月 14 日下午 2：30 （2）网络投票时间：2024 年 5 月 14 日 ①截至 2024 年 05 月 07 日下午收市时在中国证券登记结算 ...

证券代码：300247 证券简称：融捷健康 公告编号：2024-016 融捷健康科技股份有限公司 关于转让参股公司部分股权的完成公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏。 一、交易概述 融捷健康科技股份有限公司（以下简称"公司"）于2021年07月09日召开第 五届董事会第十三次会议，审议通过了《关于拟转让参股公司部分股权的议案》， 同意公司放弃安徽影联云享医疗科技有限公司（以下简称"影联云享"或"标 的公司"）的优先增资权、优先购买权并将公司所持的增资后影联云享6.8232% 的股权以人民币1313.4635万元的价格转让给讯飞医疗，并授权公司管理层办理 本次影联云享增资+股权转让的相关事宜，包括但不限于签署相关协议、办理工 商变更等；独立董事发表了同意的独立意见。交易完成后，公司继续持有标的 公司6.8333%的股权。具体内容详见公司于2021年07月13日在巨潮资讯网 （www.cninfo.com.cn）上发布的相关公告。 2021年08月05日，公司发布了《关于转让参股公司部分股权的进展公告》， 根据公司与交易对方等相关各方签署的《投资合作协议 ...

索 引 号 bm56000001/2024-00004533 分 类 发布机构 发文日期 1714352315000 马绍琴： 经查，你及一致行动人作为融捷健康科技股份有限公司原持股5%以上股东，于2022年12月19日通过融捷健康披露 减持计划。2022年12月28日、12月29日、12月30日华泰证券协助执行法院裁定书，你所持有的融捷健康股票通过集中 竞价方式减持1006.44万股，减持金额3592.87万元，占公司总股本1.25%，你及一致行动人的持股比例由5.52%下降至 4.27%。上述股份减持距离减持计划披露日不足15个交易日且超出减持计划588.84万股。马绍琴在3个月内通过证券交 易所集中竞价交易减持股份的数量超过公司股份总数的1%，且未及时履行权益变动报告、公告义务。 名 称 关于对马绍琴采取出具警示函措施的决定 关于对马绍琴采取出具警示函措施的决定 上述行为违反了《上市公司收购管理办法》（证监会令第166号）第十三条第一款、第三款,《上市公司信息披露管 理办法》（证监会令第182号）第三条第一款和《上市公司股东、董监高减持股份的若干规定》（证监会公告〔2017〕 9号）第八条、第九条的规定 ...

Financial Performance - The company's revenue for Q1 2024 was ¥176,333,541.57, representing an increase of 11.42% compared to ¥158,259,198.06 in the same period last year[5]. - Net profit attributable to shareholders was ¥20,825,834.91, marking an 86.12% increase from ¥11,189,537.80 year-on-year[5]. - Basic earnings per share rose to ¥0.0259, an increase of 86.33% compared to ¥0.0139 in the same period last year[5]. - Total operating revenue for Q1 2024 was CNY 176,333,541.57, an increase of 11.5% compared to CNY 158,259,198.06 in Q1 2023[27]. - Net profit for Q1 2024 reached CNY 28,219,984.12, representing a growth of 54.2% from CNY 18,327,304.00 in the same period last year[28]. - The company's operating profit increased to CNY 36,780,586.93, up by 45.7% from CNY 25,233,202.51 in Q1 2023[28]. - The company reported a total comprehensive income of CNY 25,504,271.67, an increase of 51.9% from CNY 16,808,961.24 in the same quarter last year[28]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 14.14% to ¥53,537,093.95, up from ¥46,906,552.61 in the previous year[5]. - Cash inflow from operating activities increased by 24.29%, attributed to higher sales collections and recovery of prior receivables[16]. - The company's cash and cash equivalents increased by 87.9% to ¥104,731,800, driven by increased sales collections and the redemption of financial products[19]. - The cash inflow from investment activities was CNY 120,353,364.99, significantly higher than CNY 35,749,988.36 in Q1 2023[30]. - The total cash and cash equivalents at the end of the period reached 223,882,753.18, up from 117,286,775.92 in the previous period[31]. - The net increase in cash and cash equivalents for the quarter was 104,731,771.65, compared to 48,986,574.33 in the same quarter last year[31]. - The cash outflow from financing activities totaled 3,210,017.12, resulting in a net cash flow from financing activities of -3,210,017.12[31]. - The impact of exchange rate changes on cash and cash equivalents was 664,760.29, contrasting with -1,288,723.24 in the previous period[31]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,250,318,370.98, a 2.35% increase from ¥1,221,559,067.16 at the end of the previous year[5]. - The total current assets reached CNY 849,978,927.57, up from CNY 818,023,730.17, indicating an increase of approximately 3.5%[23]. - The company's inventory decreased to CNY 131,316,384.57 from CNY 143,918,712.57, showing a decline of about 8.8%[23]. - The total liabilities of the company were CNY 152,107,103.35, compared to CNY 148,852,071.21 at the beginning of the period, marking an increase of approximately 1.7%[24]. - The company's accounts receivable decreased to CNY 28,774,610.77 from CNY 41,568,724.53, reflecting a decline of about 30.8%[23]. - The non-current assets totaled CNY 400,339,443.41, slightly down from CNY 403,535,336.99, indicating a decrease of about 0.5%[24]. - The company's equity remained stable at CNY 804,040,313.00, unchanged from the previous period[24]. Shareholding and Ownership - The company reported a total of 116,912,302 shares held by Rongjie Investment Holding Group, representing 14.54% of the total shares[20]. - The company has no significant changes in the shareholding structure of the top 10 shareholders, indicating stability in ownership[20]. Research and Development - Research and development expenses for the quarter were CNY 2,369,330.52, which is a 14.7% increase from CNY 2,065,738.44 in the previous year[27]. Audit Status - The company has not undergone an audit for the first quarter report[32].